Ginkgo Bioworks (US:DNA)2026-02-26 22:32Financial Data and Key Metrics Changes - In Q4 2025, cell engineering revenue was $26 million, down 26% compared to Q4 2024, with a total of 109 revenue-generating programs, a 4% decrease year-over-year [15][16] - For the full year 2025, cell engineering revenue was $133 million, down from $174 million in 2024, primarily due to customer program rationalization [15][16] - Total Adjusted EBITDA in Q4 2025 was -$36 million, an improvement from -$57 million in Q4 2024, while for the full year, it was -$167 million, up from -$293 million in 2024 [20][21] - Cash burn in Q4 2025 was $47 million, down from $55 million in Q4 2024, and for the full year, it was $171 million, a 55% decrease from $383 million in 2024 [22][24] Business Line Data and Key Metrics Changes - The biosecurity business generated $7 million in revenue in Q4 2025 and $37 million for the full year, with an operating loss improvement of 60% in Q4 2025 compared to 2024 [17][20] - Cell engineering R&D expenses decreased 44% in Q4 2025 to $28 million, and for the full year, it decreased 42% to $159 million [18][19] Market Data and Key Metrics Changes - The company is focusing on the autonomous lab market, which is expected to transform biotechnology and is seen as a high-value area for investment [3][4] - The federal government and pharmaceutical companies are significant pools of research spending, with the NIH spending $40 billion annually on lab work [31][62] Company Strategy and Development Direction - The company plans to divest its biosecurity business to focus investments on autonomous labs, aiming to demonstrate capabilities through a large autonomous lab in Boston [4][11] - The strategy includes booking sales of autonomous labs to national labs and biopharma, with a notable $47 million deal with Pacific Northwest National Laboratory [6][31] - The company aims to improve cost efficiency while investing in AI robotics and software for autonomous labs, with a cash burn guidance of $125 million to $150 million for 2026 [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of autonomous labs to replace traditional manual laboratories, emphasizing the importance of long-term orientation over short-term revenue targets [28][29] - The company highlighted the need for flexibility in lab operations and the potential for AI to enhance research productivity [59][60] Other Important Information - The company has made significant strides in reducing cash burn and controlling spending, setting a solid foundation for future investments [13][14] - The autonomous lab is positioned as a solution to save overhead costs and increase research productivity for biopharma and national labs [59][60] Q&A Session Summary Question: What is the outlook for revenue guidance in 2026? - The company will not provide revenue guidance for 2026, focusing instead on cash burn as a better reflection of ongoing services and investments in autonomous labs [24][25] Question: How does the company plan to commercialize autonomous labs? - The company plans to build autonomous labs for customers and offer cloud lab services, allowing scientists to outsource small lab work directly [61][62]